Test–retest variability and reliability of123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms

Synapse ◽  
2007 ◽  
Vol 62 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Ana M. Catafau ◽  
Santiago Bullich ◽  
Mónica Danús ◽  
María M. Penengo ◽  
Albert Cot ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Iterative Reconstruction ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Striatal Dopamine ◽  
Reconstruction Algorithms ◽  
Dopamine D2

scholarly journals Effect of Zishenpingchan Granule on Neurobehavioral Manifestations and the Activity and Gene Expression of Striatal Dopamine D1 and D2 Receptors of Rats with Levodopa-Induced Dyskinesias

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Qing Ye ◽  
Xiao-Lei Yuan ◽  
Jie Zhou ◽  
Can-xing Yuan ◽  
Xu-ming Yang
Keyword(s):  
Gene Expression ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
D2 Receptors ◽  
Striatal Dopamine ◽  
Control Group ◽  
Indirect Pathway ◽  
Dopamine D2 ◽  
D1 And D2 Receptors ◽  
Neurobehavioral Manifestations

This study was performed to observe the effects of Zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine D1 and D2 receptors of rats with levodopa-induced dyskinesias (LID). We established normal control group, LID model group, and TCM intervention group. Each group received treatment for 4 weeks. Artificial neural network (ANN) was applied to excavate the main factor influencing variation in neurobehavioral manifestations of rats with LID. The results showed that overactivation in direct pathway mediated by dopamine D1 receptor and overinhibition in indirect pathway mediated by dopamine D2 receptor may be the main mechanism of LID. TCM increased the efficacy time of LD to ameliorate LID symptoms effectively mainly by upregulating dopamine D2 receptor gene expression.

Striatal dopamine D2 receptor occupancy in patients treated with olanzapine

1998 ◽  
Vol 29 (1-2) ◽  
pp. 166 ◽  
Author(s):  
T.J. Raedler ◽  
M.B. Knable ◽  
T. Lafargue ◽  
D. Pickar ◽  
D.R. Weinberger
Keyword(s):  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Receptor Occupancy ◽  
Striatal Dopamine ◽  
Dopamine D2 ◽  
Dopamine D2 Receptor Occupancy

scholarly journals Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability

2011 ◽  
Vol 18 (6) ◽  
pp. 908-911 ◽  
Author(s):  
Cleo L. Crunelle ◽  
Elsmarieke van de Giessen ◽  
Sybille Schulz ◽  
Louk J. M. J. Vanderschuren ◽  
Kora de Bruin ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Striatal Dopamine ◽  
Dopamine D2 ◽  
Cannabinoid 1 Receptor
Sign in / Sign up

Export Citation Format

Share Document